Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
08/11/201911:33Business WireFDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular R...NASDAQ:XLRNAcceleron Pharma Inc
06/11/201908:05Business WireAcceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual MeetingNASDAQ:XLRNAcceleron Pharma Inc
06/11/201906:59Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XLRNAcceleron Pharma Inc
06/11/201906:55Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
06/11/201906:53Business WireAcceleron Reports Third Quarter 2019 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
29/10/201906:00Business WireAcceleron to Webcast Third Quarter 2019 Operating and Financial Results on November 6, 2019NASDAQ:XLRNAcceleron Pharma Inc
16/09/201915:30Business WireAcceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular DystrophyNASDAQ:XLRNAcceleron Pharma Inc
09/09/201906:00Business WireAcceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial HypertensionNASDAQ:XLRNAcceleron Pharma Inc
12/08/201915:19Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
05/08/201915:05Business WireAcceleron Reports Second Quarter 2019 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
24/07/201906:00Business WireAcceleron to Webcast Second Quarter 2019 Operating and Financial Results on August 5, 2019NASDAQ:XLRNAcceleron Pharma Inc
05/07/201908:54Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:XLRNAcceleron Pharma Inc
26/06/201906:35Business WireAcceleron Completes Target Enrollment in the PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial HypertensionNASDAQ:XLRNAcceleron Pharma Inc
10/06/201906:00Business WireAcceleron Announces Retirement of Director and Co-Founder Tom ManiatisNASDAQ:XLRNAcceleron Pharma Inc
07/06/201915:39Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:XLRNAcceleron Pharma Inc
04/06/201907:24Dow Jones NewsFDA Accepts Celgene, Acceleron BLA for Anemia Drug LuspaterceptNASDAQ:XLRNAcceleron Pharma Inc
04/06/201906:30Business WireCelgene Corp. & Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Synd...NASDAQ:XLRNAcceleron Pharma Inc
14/05/201906:00Business WireAcceleron to Present at the UBS Global Healthcare ConferenceNASDAQ:XLRNAcceleron Pharma Inc
09/05/201915:05Business WireAcceleron Reports First Quarter 2019 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
01/05/201906:00Business WireAcceleron to Webcast First Quarter 2019 Operating and Financial Results on May 9, 2019NASDAQ:XLRNAcceleron Pharma Inc
26/04/201906:30Business WireCelgene Corp. & Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medi...NASDAQ:XLRNAcceleron Pharma Inc
12/04/201915:23Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XLRNAcceleron Pharma Inc
12/04/201915:21Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XLRNAcceleron Pharma Inc
05/04/201915:01Business WireAcceleron Announces Departure of Chief Medical OfficerNASDAQ:XLRNAcceleron Pharma Inc
05/04/201909:24Dow Jones NewsCelgene Files BLA for Anemia Drug Luspatercept With FDANASDAQ:XLRNAcceleron Pharma Inc
05/04/201908:28Business WireCelgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDANASDAQ:XLRNAcceleron Pharma Inc
04/04/201915:05Business WireAcceleron Discontinues Development of Phase 1 Molecule ACE-2494NASDAQ:XLRNAcceleron Pharma Inc
05/03/201906:00Business WireAcceleron Receives FDA Orphan Drug Designation for ACE-083 in Charcot-Marie-Tooth DiseaseNASDAQ:XLRNAcceleron Pharma Inc
27/02/201915:31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:XLRNAcceleron Pharma Inc
27/02/201915:22Edgar (US Regulatory)Annual Report (10-k)NASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN

Su Consulta Reciente

Delayed Upgrade Clock